ACE2 Antagonizes VEGFa to Reduce Vascular Permeability During Acute Lung Injury | Zendy

Xiaobo Yu | Zendy; Qiang Lin | Zendy; Xiong Qin | Zendy; Zheng Ruan | Zendy; Jianhua Zhou | Zendy; Zhifeng Lin | Zendy; Yijiang Su | Zendy; Jian Zheng | Zendy; Zhenwei Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ACE2 Antagonizes VEGFa to Reduce Vascular Permeability During Acute Lung Injury

Author(s) -

Xiaobo Yu,

Qiang Lin,

Xiong Qin,

Zheng Ruan,

Jianhua Zhou,

Zhifeng Lin,

Yijiang Su,

Jian Zheng,

Zhenwei Liu

Publication year - 2016

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000443056

Subject(s) - vascular endothelial growth factor a , vascular permeability , angiotensin converting enzyme 2 , lung , bleomycin , vascular endothelial growth factor , pharmacology , medicine , chemistry , vegf receptors , chemotherapy , covid-19 , disease , infectious disease (medical specialty)

Angiotensin converting enzyme 2 (ACE2) treatment suppresses the severity of acute lung injury (ALI), through antagonizing hydrolyzing angiotensin II (AngII) and the ALI-induced apoptosis of pulmonary endothelial cells. Nevertheless, the effects of ACE2 on vessel permeability and its relationship with vascular endothelial growth factor a (VEGFa) remain ill-defined. In the current study, we examined the relationship between ACE2 and VEGFa in ALI model in mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research